California based biotech Geron, which had been conducting the world’s first clinical trial of a human embryonic stem cell-based therapy for spinal cord injury, announced it was halting its trial and leaving the stem cell field all together. Geron attributed financial difficulties rather than any problems with the trial itself to its exit from the stem cell therapeutics areana. However, the move is expected to be widely seen as a setback for the field, already facing controversy around the use of human embryonic tissue. Advanced Cell Technology, also facing financial difficulties, is now the only company conducting a clinical trial involving human embryonic stem cells.
Click here to read more.Share this: